Literature DB >> 20425334

Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

David Dingli1, Ayalew Tefferi.   

Abstract

Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease. It is usually well tolerated and cheap and has been proven effective in many studies for the prevention of thrombohemorrhagic complications associated with these disorders. However, many clinicians are reluctant to use it because of the perceived risk of progression to acute leukemia. Several recent, large studies have given this drug a new lease on life. Relevant results from these studies are discussed, and the risk of leukemia is placed in perspective to demonstrate that hydroxyurea remains the drug of choice in patients with either of these disorders.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 20425334     DOI： 10.1007/s11899-006-0025-4

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  62 in total

Review 1.  The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.

Authors:  A Tefferi
Journal:  Mayo Clin Proc       Date:  1998-12       Impact factor: 7.616

2.  Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks.

Authors:  A Chabes; L Thelander
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

Review 3.  New drugs in essential thrombocythemia and polycythemia vera.

Authors:  A Tefferi; M A Elliott; L A Solberg; M N Silverstein
Journal:  Blood Rev       Date:  1997-03       Impact factor: 8.250

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  [A case for diagnosis: Hydrea pseudo-dermatomyositis].

Authors:  J L Perrot; F Cambazard
Journal:  Ann Dermatol Venereol       Date:  1994       Impact factor: 0.777

Review 6.  Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Authors:  J J Michiels; J Kutti; P Stark; M Bazzan; L Gugliotta; R Marchioli; M Griesshammer; P J van Genderen; J Brière; J J Kiladjian; T Barbui; G Finazzi; N I Berlin; T C Pearson; A C Green; S M Fruchtmann; R T Silver; E Hansmann; A Wehmeier; E Lengfelder; R Landolfi; H M Kvasnicka; H Hasselbalch; F Cervantes; J Thiele
Journal:  Neth J Med       Date:  1999-02       Impact factor: 1.422

Review 7.  Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".

Authors:  Y Najean; J D Rain; C Dresch; A Goguel; F Lejeune; M Echard; M J Grange
Journal:  Leuk Lymphoma       Date:  1996-09

8.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 9.  The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.

Authors:  C J McGinn; T J Kinsella
Journal:  Semin Oncol       Date:  1992-08       Impact factor: 4.929

10.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640
View more
  6 in total

1.  Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera.

Authors:  Srecko Marusic; Nives Gojo-Tomic; Vesna Bacic-Vrca; Velimir Bozikov
Journal:  Eur J Clin Pharmacol       Date:  2010-12-14       Impact factor: 2.953

2.  Burning feet in polycythemia vera - peripheral sensorimotor axonal neuropathy with erythromelalgia.

Authors:  Uwe Wollina
Journal:  Int J Gen Med       Date:  2015-02-02

3.  Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low-dose methotrexate.

Authors:  Sarah Mattessich; Katalin Ferenczi; Jun Lu
Journal:  JAAD Case Rep       Date:  2017-09-08

Review 4.  Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Authors:  Victor R Gordeuk; Nigel S Key; Josef T Prchal
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

5.  Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.

Authors:  Hanne Fredly; Bjørn Tore Gjertsen; Oystein Bruserud
Journal:  Clin Epigenetics       Date:  2013-07-30       Impact factor: 6.551

6.  Laser Photobiomodulation for a Complex Patient with Severe Hydroxyurea-Induced Oral Ulcerations.

Authors:  Marco Cabras; Adriana Cafaro; Alessio Gambino; Roberto Broccoletti; Ercole Romagnoli; Davide Marina; Paolo G Arduino
Journal:  Case Rep Dent       Date:  2016-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.